Dexcom Share Price (NASDAQ: DXCM)

$82.25

▲

1.63

(2.02%)

Last updated on August 23, 2025 at 1:29 AM IST

$₹

Check the interactive Dexcom Stock chart to analyse performance

Dexcom stock performance

as on August 23, 2025 at 1:29 AM IST

Today's Low:$80.67
Today's High:$82.30
$82.25
1.92%
Downside
Day's Volatility :1.98%
Upside
0.06%
52 Weeks Low:$57.52
52 Weeks High:$93.25
$82.25
30.07%
Downside
52 Weeks Volatility :38.32%
Upside
11.8%

Dexcom Stock Returns

Period	Dexcom, Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-3.54%	6.0%	14.7%
6 Months	-9.3%	-6.4%	11.5%
1 Year	11.73%	-11.1%	20.2%
3 Years	-6.86%	6.7%	72.9%

Dexcom, Inc. Key Stats

Check Dexcom key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$80.62
Open	$81.0
Today's High	$82.3
Today's Low	$80.67
Market Capitalization	$31.6B
Today's Volume	$3.7M
52 Week High	$93.25
52 Week Low	$57.52
Revenue TTM	$4.3B
EBITDA	$923.3M
Earnings Per Share (EPS)	$1.42
PE Ratio	56.77
Profit Margin	13.29%
Quarterly Earnings Growth YOY	0.27%
Return On Equity TTM	22.83%

Stock Returns calculator for Dexcom Stock including INR - Dollar returns

The Dexcom stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Dexcom investment value today

Current value as on today

₹1,15,962

Returns

₹15,962

(+15.96%)

Returns from Dexcom Stock

₹11,647 (+11.65%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Dexcom Stock

-8%

Period: Jul 24, 2025 to Aug 23, 2025. Change in 30 Days versus previous period

Search interest for Dexcom Stock from India on INDmoney has decreased by -8% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Dexcom Stock

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	3170	10.33	0.06%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	5581	30.81	0.18%

Global Institutional Holdings in Dexcom, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
12.32%
BlackRock Inc
10.01%
Baillie Gifford & Co Limited.
4.26%
State Street Corp
4.25%
Jennison Associates LLC
2.94%
Geode Capital Management, LLC
2.65%

Analyst Recommendation on Dexcom Stock

Rating

Trend

Buy

86%Buy

13%Hold

0%Sell

Based on 30 Wall street analysts offering stock ratings for Dexcom(by analysts ranked 0 to 5 stars)

Dexcom Share Price Target

What analysts predicted

Upside of 24.11%

Target:

$102.08

Current:

$82.25

Dexcom share price target is $102.08, a slight Upside of 24.11% compared to current price of $82.25 as per analysts' prediction.

Dexcom Stock Insights

Price Movement
In the last 1 month, DXCM stock has moved down by -5.1%
Increasing Revenue
Dexcom, Inc. has shown positive revenue growth over the last two quarters. The revenue increased from $1.03 billion to $1.15 billion, marking an average growth of 10.5% each quarter.
Increasing Net Profit
Dexcom, Inc. has shown strong profit growth over the last two quarters. The company's net profit increased from $105.4 million to $179.8 million, representing an average quarterly growth of 41.4%. This positive trend indicates that the company's profitability has been consistently improving.
DXCM vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 34.1% return, outperforming this stock by 23.0%
DXCM vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 158.0% return, outperforming this stock by 162.2%
Price to Sales
Dexcom, Inc. has a Price-to-Sales (P/S) Ratio of $7.5, meaning that investors are willing to pay $7.5 for every $1 of sales the company generates. In comparison, Boston Scientific Corp. has a higher P/S Ratio of $8.5, indicating that investors value its sales more than those of Dexcom. This suggests that investors view Boston Scientific as potentially having stronger sales growth or overall better performance.

Dexcom, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$1.5B	↑ 43.08%
Net Income	$101.1M	↓ 179.54%
Net Profit Margin	6.85%	↑ 19.17%

	FY20	Y/Y Change
Revenue	$1.9B	↑ 30.54%
Net Income	$493.6M	↑ 388.23%
Net Profit Margin	25.62%	↑ 18.77%

	FY21	Y/Y Change
Revenue	$2.4B	↑ 27.08%
Net Income	$216.9M	↓ 56.06%
Net Profit Margin	8.86%	↓ 16.76%

	FY22	Y/Y Change
Revenue	$2.9B	↑ 18.84%
Net Income	$341.2M	↑ 57.31%
Net Profit Margin	11.73%	↑ 2.87%

	FY23	Y/Y Change
Revenue	$3.6B	↑ 24.49%
Net Income	$541.5M	↑ 58.7%
Net Profit Margin	14.95%	↑ 3.22%

	FY24	Y/Y Change
Revenue	$4.0B	↑ 11.34%
Net Income	$576.2M	↑ 6.41%
Net Profit Margin	14.29%	↓ 0.66%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$921.0M	↓ 10.97%
Net Income	$146.4M	↓ 42.88%
Net Profit Margin	15.9%	↓ 8.88%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 9.04%
Net Income	$143.5M	↓ 1.98%
Net Profit Margin	14.29%	↓ 1.61%

	Q3 FY24	Q/Q Change
Revenue	$994.2M	↓ 1.01%
Net Income	$134.6M	↓ 6.2%
Net Profit Margin	13.54%	↓ 0.75%

	Q4 FY24	Q/Q Change
Revenue	$1.1B	↑ 12.0%
Net Income	$151.7M	↑ 12.7%
Net Profit Margin	13.62%	↑ 0.08%

	Q1 FY25	Q/Q Change
Revenue	$1.0B	↓ 6.96%
Net Income	$105.4M	↓ 30.52%
Net Profit Margin	10.17%	↓ 3.45%

	Q2 FY25	Q/Q Change
Revenue	$1.2B	↑ 11.69%
Net Income	$179.8M	↑ 70.59%
Net Profit Margin	15.54%	↑ 5.37%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$931.5M	↑ 40.31%

	FY20	Y/Y Change
Profit	$1.3B	↑ 37.42%

	FY21	Y/Y Change
Profit	$1.7B	↑ 31.28%

	FY22	Y/Y Change
Profit	$1.9B	↑ 12.06%

	FY23	Y/Y Change
Profit	$2.3B	↑ 21.55%

	FY24	Y/Y Change
Profit	$2.4B	↑ 6.52%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$561.9M	↓ 14.42%

	Q2 FY24	Q/Q Change
Profit	$626.7M	↑ 11.53%

	Q3 FY24	Q/Q Change
Profit	$593.8M	↓ 5.25%

	Q4 FY24	Q/Q Change
Profit	$655.8M	↑ 10.44%

	Q1 FY25	Q/Q Change
Profit	$589.0M	↓ 10.19%

	Q2 FY25	Q/Q Change
Profit	$688.8M	↑ 16.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$314.5M	↑ 155.28%
Investing Cash Flow	$-1.0B	↑ 626.18%
Financing Cash Flow	$10.7M	↓ 98.49%

	FY20	Y/Y Change
Operating Cash Flow	$475.6M	↑ 51.22%
Investing Cash Flow	$-1.0B	↑ 0.28%
Financing Cash Flow	$912.1M	↑ 8424.3%

	FY21	Y/Y Change
Operating Cash Flow	$442.5M	↓ 6.96%
Investing Cash Flow	$-216.1M	↓ 78.77%
Financing Cash Flow	$10.4M	↓ 98.86%

	FY22	Y/Y Change
Operating Cash Flow	$669.5M	↑ 51.3%
Investing Cash Flow	$-521.5M	↑ 141.32%
Financing Cash Flow	$-552.5M	↓ 5412.5%

	FY23	Y/Y Change
Operating Cash Flow	$748.5M	↑ 11.8%
Investing Cash Flow	$-507.2M	↓ 2.74%
Financing Cash Flow	$-318.6M	↓ 42.33%

	FY24	Y/Y Change
Operating Cash Flow	$989.5M	↑ 32.2%
Investing Cash Flow	$-207.5M	↓ 59.09%
Financing Cash Flow	$-734.8M	↑ 130.63%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$209.2M	↑ 56.59%
Investing Cash Flow	$74.8M	↓ 81.97%
Financing Cash Flow	$4.7M	↓ 100.74%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$279.4M	↑ 33.56%
Investing Cash Flow	$-188.9M	↓ 352.54%
Financing Cash Flow	$-1.4M	↓ 129.79%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$199.5M	↓ 28.6%
Investing Cash Flow	$210.3M	↓ 211.33%
Financing Cash Flow	$-736.5M	↑ 52507.14%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$301.4M	↑ 51.08%
Investing Cash Flow	$-303.7M	↓ 244.41%
Financing Cash Flow	$-1.6M	↓ 99.78%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$183.8M	↓ 39.02%
Investing Cash Flow	$100.2M	↓ 132.99%
Financing Cash Flow	$12.5M	↓ 881.25%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$303.0M	↑ 64.85%
Investing Cash Flow	$-63.6M	↓ 163.47%
Financing Cash Flow	$-1.7M	↓ 113.6%

Dexcom Technicals Summary

Sell

Neutral

Buy

Dexcom is currently in a neutral trading position according to technical analysis indicators.

Dexcom, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Dexcom, Inc.	-7.51%	-9.3%	11.73%	-6.86%	-23.45%
Stryker Corporation	-2.33%	1.6%	11.24%	81.88%	107.9%
Medtronic Plc	-0.24%	2.83%	3.78%	0.63%	-9.62%
Edwards Lifesciences Corp.	2.2%	12.37%	18.92%	-15.41%	1.75%
Boston Scientific Corp.	0.01%	1.69%	33.57%	154.07%	167.79%
Abbott Laboratories	4.76%	-1.77%	17.62%	25.19%	29.36%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Dexcom, Inc.	56.77	56.77	1.32	2.05	0.23	0.06	NA	6.56
Stryker Corporation	51.04	51.04	2.23	13.49	0.14	0.08	0.01	55.43
Medtronic Plc	25.17	25.17	2.19	5.46	0.1	0.04	0.03	37.46
Edwards Lifesciences Corp.	33.96	33.96	4.86	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.63	62.63	1.84	2.98	0.12	0.05	NA	15.14
Abbott Laboratories	16.56	16.56	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Dexcom, Inc.	Buy	$31.6B	-23.45%	56.77	13.29%
Stryker Corporation	Buy	$147.1B	107.9%	51.04	12.25%
Medtronic Plc	Buy	$116.7B	-9.62%	25.17	13.63%
Edwards Lifesciences Corp.	Buy	$47.6B	1.75%	33.96	72.96%
Boston Scientific Corp.	Buy	$155.9B	167.79%	62.63	13.55%
Abbott Laboratories	Buy	$229.7B	29.36%	16.56	32.43%

About Dexcom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Organization	Dexcom
Employees	10200
CEO	Mr. Kevin Ronald Sayer
Industry	Health Technology

Key Management of Dexcom, Inc.

Name	Title
Mr. Kevin Ronald Sayer	Executive Chairman & CEO
Mr. Jacob Steven Leach	President & COO
Mr. Jereme M. Sylvain CPA	Executive VP, CFO & Chief Accounting Officer
Ms. Sadie M. Stern	Executive VP & Chief Human Resources Officer
Mr. Girish Naganathan	Executive VP & CTO
Mr. Sean Christensen	Vice President of Finance and Investor Relations
Mr. Matthew Dolan	Executive Vice President of Strategy & Corporate Development
Ms. Leverne Marsh	Executive Vice President of Marketing
Mr. Donald M. Abbey	Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs
Mr. Jon Coleman	Executive VP & Chief Commercial Officer

Important FAQs about investing in DXCM Stock from India :

What is Dexcom share price today?

Dexcom share price today is $82.25 as on August 23, 2025 at 1:29 AM IST at the close of the market. Dexcom share today touched a day high of $82.30 and a low of $80.67.

What is the 52 week high and 52 week low for Dexcom share?

Dexcom share touched a 52 week high of $93.25 and a 52 week low of $57.52. Dexcom stock price today i.e. August 23, 2025 at 1:29 AM IST is closed at $82.25, lower by 11.8% versus the 52 week high.

How to invest in Dexcom Stock (DXCM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Dexcom on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Dexcom Shares that will get you 0.0182 shares as per Dexcom share price of $82.25 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Dexcom Stock (DXCM) from India?

Indian investors can start investing in Dexcom (DXCM) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Dexcom stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Based on Dexcom share’s latest price of $82.25 as on August 23, 2025 at 1:29 AM IST, you will get 0.1216 shares of Dexcom. Learn more about fractional shares .

What are the returns that Dexcom has given to Indian investors in the last 5 years?

Dexcom stock has given -23.45% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?